P-CABs are a novel class of medicines that block acid secretion in the stomach. Approximately 30% of GERD patients have erosive esophagitis. PPIs require activation by gastric acid, but they are unstable in the presence of acid. x2022; Commercialize vonoprazan in the United States. The PPI class is currently the first-line treatment of acid-related GI diseases. Vonoprazan Vonoprazan has a differentiated mechanism of action from PPIs. The results of the trial are summarized below. In Japan and Asia, separate clinical trials were conducted for each of these indications. We believe that the design of these trials may have contributed to their results. We also plan to employ modern digital diary collection tools. The doses studied have ranged from 1 to 120 mg with durations up to one year. Revaprazan is marketed by Yuhan Corporation in South Korea. The FDA will not approve the NDA without an approved REMS, if required. In addition, a product may be eligible for accelerated approval. If that were to happen, the trading price of our common stock could decline. The historical failure rate for product candidates in our industry is high. & & For the foregoing reasons, our ongoing clinical trials may not be successful. These changes will lead to additional costs and increase our overall risk exposure. We may also be subject to additional regulation in the conduct of our business. Claims could also be asserted under state consumer protection acts. Insurance coverage is increasingly expensive. Evolving judicial interpretation of patent law could also adversely affect our business. Furthermore, many of our current directors were appointed by our principal stockholders. We have never declared or paid any cash dividend on our common stock. Investors may find our common stock less attractive if we rely on these exemptions.
